# To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

> **NCT00552305** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 370 (actual)

## Conditions studied

- Partial Epilepsies

## Interventions

- **DRUG:** lacosamide

## Key facts

- **NCT ID:** NCT00552305
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 370 (ACTUAL)
- **Last updated:** 2018-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00552305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00552305, "To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00552305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*